Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 30, 2003. The report is a notification of changes in directors' interests in the company's Ordinary Shares, specifically regarding transactions within the GlaxoSmithKline Employee Trust (GSK Trust).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to employee incentive plans.
Material Changes
On April 25, 2003, the GSK Trust executed the following transactions on behalf of a participant in the SmithKline Beecham Mid Term Incentive Plan:
- Sold 1,351 Ordinary Shares at a price of £12.4725 per share.
- Transferred 1,298 Ordinary Shares to the participant.
These transactions were advised to the company on April 28, 2003.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust for current and former employees, and that Directors Dr. J-P Garnier and Mr. J D Coombe hold interests in the trust shares similarly to other employees.
Investor Verification Points
- Verify the total number of shares held by the GSK Trust and the specific allocation to directors Dr. J-P Garnier and Mr. J D Coombe.
- Confirm the terms of the SmithKline Beecham Mid Term Incentive Plan to understand the context of the share sales and transfers.
- Check subsequent filings for any further changes in director interests or trust holdings.